Aytu BioScience Net Worth
Aytu BioScience Net Worth Breakdown | AYTU |
Aytu BioScience Net Worth Analysis
Aytu BioScience's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Aytu BioScience's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Aytu BioScience's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Aytu BioScience's net worth analysis. One common approach is to calculate Aytu BioScience's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Aytu BioScience's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Aytu BioScience's net worth. This approach calculates the present value of Aytu BioScience's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Aytu BioScience's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Aytu BioScience's net worth. This involves comparing Aytu BioScience's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Aytu BioScience's net worth relative to its peers.
Enterprise Value |
|
To determine if Aytu BioScience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Aytu BioScience's net worth research are outlined below:
| Aytu BioScience is way too risky over 90 days horizon | |
| Aytu BioScience appears to be risky and price may revert if volatility continues | |
| Aytu BioScience has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 81 M. Net Loss for the year was (15.84 M) with profit before overhead, payroll, taxes, and interest of 52.89 M. | |
| Aytu BioScience currently holds about 23.81 M in cash with (1.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Aytu BioScience has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Lake Street Sees Big Upside for Aytu Biosciences After EXXUA Acquisition |
Aytu BioScience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Aytu BioScience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Aytu BioScience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Aytu BioScience Target Price Consensus
Aytu target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Aytu BioScience's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Buy |
Most Aytu analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Aytu stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Aytu BioScience, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationAytu BioScience Target Price Projection
Aytu BioScience's current and average target prices are 2.46 and 9.00, respectively. The current price of Aytu BioScience is the price at which Aytu BioScience is currently trading. On the other hand, Aytu BioScience's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Aytu BioScience Market Quote on 31st of July 2025
Target Price
Analyst Consensus On Aytu BioScience Target Price
Know Aytu BioScience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Aytu BioScience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Aytu BioScience backward and forwards among themselves. Aytu BioScience's institutional investor refers to the entity that pools money to purchase Aytu BioScience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Acadian Asset Management Llc | 2025-03-31 | 14.6 K | Tower Research Capital Llc | 2025-03-31 | 4.7 K | Mccormack Advisors International | 2025-03-31 | 3.6 K | Advisor Group Holdings, Inc. | 2025-03-31 | 300 | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 290 | Ubs Group Ag | 2025-03-31 | 262 | Wells Fargo & Co | 2025-03-31 | 124 | Bank Of America Corp | 2025-03-31 | 103 | Atlantic Trust Group, Llc | 2025-03-31 | 83.0 | Nantahala Capital Management, Llc | 2025-03-31 | 1.1 M | Kanen Wealth Management Llc | 2025-06-30 | 573.4 K |
Follow Aytu BioScience's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.8 M.Market Cap |
|
Project Aytu BioScience's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.46) | (1.53) | |
| Return On Capital Employed | (1.07) | (1.02) | |
| Return On Assets | (0.46) | (0.49) | |
| Return On Equity | (1.04) | (1.09) |
When accessing Aytu BioScience's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Aytu BioScience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Aytu BioScience's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Aytu BioScience's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Aytu BioScience. Check Aytu BioScience's Beneish M Score to see the likelihood of Aytu BioScience's management manipulating its earnings.
Evaluate Aytu BioScience's management efficiency
Return On Tangible Assets is likely to drop to -1.53 in 2025. Return On Capital Employed is likely to gain to -1.02 in 2025. At this time, Aytu BioScience's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 142.6 M in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 4.9 M in 2025. Aytu BioScience's management efficiency ratios could be used to measure how well Aytu BioScience manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 596.6 K | 626.4 K | |
| Tangible Book Value Per Share | -314.5 K | -298.8 K | |
| Enterprise Value Over EBITDA | (377.02) | (358.17) | |
| Price Book Value Ratio | 3.34 | 3.50 | |
| Enterprise Value Multiple | (377.02) | (358.17) | |
| Price Fair Value | 3.34 | 3.50 | |
| Enterprise Value | 19.9 M | 22.1 M |
Understanding the operational decisions made by Aytu BioScience management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 0.3179 | Revenue | Quarterly Revenue Growth 0.316 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aytu BioScience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aytu BioScience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aytu BioScience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aytu BioScience time-series forecasting models is one of many Aytu BioScience's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aytu BioScience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Aytu BioScience Earnings Estimation Breakdown
The calculation of Aytu BioScience's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Aytu BioScience is estimated to be -0.0625 with the future projection ranging from a low of -0.0625 to a high of -0.0625. Please be aware that this consensus of annual earnings estimates for Aytu BioScience is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.06 Lowest | Expected EPS | -0.06 Highest |
Aytu BioScience Earnings Projection Consensus
Suppose the current estimates of Aytu BioScience's value are higher than the current market price of the Aytu BioScience stock. In this case, investors may conclude that Aytu BioScience is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Aytu BioScience's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2025 | Current EPS (TTM) | |
| 2 | 39.7% | 0.13 | -0.0625 | -1.49 |
Aytu BioScience Earnings per Share Projection vs Actual
Actual Earning per Share of Aytu BioScience refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Aytu BioScience predict the company's earnings will be in the future. The higher the earnings per share of Aytu BioScience, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Aytu BioScience Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Aytu BioScience, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Aytu BioScience should always be considered in relation to other companies to make a more educated investment decision.Aytu Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Aytu BioScience's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-05-13 | 2025-03-31 | -0.64 | 0.21 | 0.85 | 132 | ||
2025-02-05 | 2024-12-31 | -0.28 | 0.13 | 0.41 | 146 | ||
2024-11-12 | 2024-09-30 | -0.34 | -0.15 | 0.19 | 55 | ||
2024-09-25 | 2024-06-30 | -0.45 | -0.82 | -0.37 | 82 | ||
2024-05-15 | 2024-03-31 | -0.64 | -0.52 | 0.12 | 18 | ||
2024-02-14 | 2023-12-31 | -0.25 | -0.04 | 0.21 | 84 | ||
2023-11-14 | 2023-09-30 | -0.04 | -1.48 | -1.44 | 3600 | ||
2023-09-27 | 2023-06-30 | -0.95 | -0.59 | 0.36 | 37 | ||
2023-05-11 | 2023-03-31 | -0.63 | -1.93 | -1.3 | 206 | ||
2023-02-21 | 2022-12-31 | -1.6 | -1.31 | 0.29 | 18 | ||
2022-11-14 | 2022-09-30 | -3.6 | -1.2 | 2.4 | 66 | ||
2022-09-27 | 2022-06-30 | -7.4 | -9.8 | -2.4 | 32 | ||
2022-05-16 | 2022-03-31 | -8.2 | -35.8 | -27.6 | 336 | ||
2022-02-14 | 2021-12-31 | -11.6 | -8.8 | 2.8 | 24 | ||
2021-11-15 | 2021-09-30 | -9.8 | -21.8 | -12.0 | 122 | ||
2021-09-27 | 2021-06-30 | -9.8 | -15.0 | -5.2 | 53 | ||
2021-05-17 | 2021-03-31 | -6.3 | -28.2 | -21.9 | 347 | ||
2021-02-11 | 2020-12-31 | -8.8 | -14.0 | -5.2 | 59 | ||
2020-11-12 | 2020-09-30 | -11 | -8.0 | 3.0 | 27 | ||
2020-09-24 | 2020-06-30 | -0.35 | -0.2 | 0.15 | 42 | ||
2020-05-14 | 2020-03-31 | -44 | -30.0 | 14.0 | 31 | ||
2020-02-13 | 2019-12-31 | -49 | -2.0 | 47.0 | 95 | ||
2019-11-14 | 2019-09-30 | -55 | -64.0 | -9.0 | 16 | ||
2019-09-26 | 2019-06-30 | -66 | -64.0 | 2.0 | 3 | ||
2019-05-14 | 2019-03-31 | -116 | -100.0 | 16.0 | 13 | ||
2019-02-07 | 2018-12-31 | -79 | -128.0 | -49.0 | 62 | ||
2018-11-07 | 2018-09-30 | -290 | -392.0 | -102.0 | 35 | ||
2018-09-06 | 2018-06-30 | -18.6 | 0.29 | 18.89 | 101 | ||
2018-05-14 | 2018-03-31 | -4000 | -324.0 | 3676.0 | 91 | ||
2018-02-08 | 2017-12-31 | -7120 | -3560.0 | 3560.0 | 50 | ||
2017-11-09 | 2017-09-30 | -30400 | -7040.0 | 23360.0 | 76 | ||
2017-08-31 | 2017-06-30 | -34400 | -16640.0 | 17760.0 | 51 | ||
2017-05-11 | 2017-03-31 | -1466.67 | -1800.0 | -333.33 | 22 | ||
2017-02-09 | 2016-12-31 | -2640 | -2440.0 | 200.0 | 7 | ||
2016-11-07 | 2016-09-30 | -3360 | -4680.0 | -1320.0 | 39 | ||
2016-09-01 | 2016-06-30 | -3120 | -9092.0 | -5972.0 | 191 |
Aytu BioScience Corporate Management
| Russ McMahen | Senior Development | Profile | |
| Christopher Brooke | Chief Officer | Profile | |
| Margaret Cabano | Vice Operations | Profile | |
| Topher Brooke | Chief Officer | Profile | |
| Greg Pyszczymuka | Chief Officer | Profile |
Already Invested in Aytu BioScience?
The danger of trading Aytu BioScience is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Aytu BioScience is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Aytu BioScience. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Aytu BioScience is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.